<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00068653</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000327805</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-C-2563</secondary_id>
    <secondary_id>ZENECA-1839US/0252</secondary_id>
    <nct_id>NCT00068653</nct_id>
  </id_info>
  <brief_title>Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Study of the Combination of ZD1839 (Iressa) and Celecoxib in Patients With Platinum Refractory Non-Small Cell Lung Cance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      tumor cell growth. Celecoxib may slow the growth of cancer by stopping blood flow to the&#xD;
      tumor. Combining gefitinib with celecoxib may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining gefitinib with celecoxib in&#xD;
      treating patients who have non-small cell lung cancer that is refractory to platinum-based&#xD;
      chemotherapy (such as cisplatin or carboplatin).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate in patients with platinum-refractory non-small cell lung&#xD;
           cancer treated with gefitinib and celecoxib.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the progression-free and overall survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive oral gefitinib once daily and oral celecoxib twice daily on days&#xD;
      1-28. Treatment repeats every 28 days for up to 3 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed for up to 6 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18-27 patients will be accrued for this study within 22 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Every 2 cycles; after the 1st 4 cycles, every month by clinical exam &amp; every 3 months radiological evaluation</time_frame>
    <description>CT scan chest/abdomen; Assessments of complete response (CR) or partial response (PR)require confirmation 4 weeks or later.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Every 2 cycles; after the 1st 4 cycles, every month by clinical exam &amp; every 3 months radiological evaluation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Every 2 cycles; after the 1st 4 cycles, every month by clinical exam &amp; every 3 months radiological evaluation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of this drug combination</measure>
    <time_frame>Every 2 weeks; Every month after 4 cycles if the patient has not developed &gt; Grade 2 toxicity</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Celecoxib &amp; ZD1839</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Celecoxib: 400mg orally two times a day, taken with meals.&#xD;
ZD1839: 250 mg po every day, taken with or without food.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Celecoxib 400mg orally two times a day, taken with meals.</description>
    <arm_group_label>Celecoxib &amp; ZD1839</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD1839</intervention_name>
    <description>ZD1839 250 mg po every day, taken with or without food.</description>
    <arm_group_label>Celecoxib &amp; ZD1839</arm_group_label>
    <other_name>Iressa</other_name>
    <other_name>Gefitinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)&#xD;
&#xD;
          -  Progression of disease during platinum-based (cisplatin or carboplatin) chemotherapy&#xD;
             or within 3 months of completing chemotherapy&#xD;
&#xD;
               -  Treatment with other agents since prior platinum-based chemotherapy allowed&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Target lesions within a prior radiation field must have documented evidence of&#xD;
                  progression at least 8 weeks after the completion of radiotherapy&#xD;
&#xD;
          -  No active brain or leptomeningeal metastases&#xD;
&#xD;
               -  Treated brain metastases allowed at least 4 weeks after the completion of&#xD;
                  appropriate therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times ULN (if alkaline phosphatase is no greater than ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 5 times ULN (if AST and ALT are greater than ULN)&#xD;
&#xD;
          -  No history of chronic hepatitis&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No active thromboembolic event within the past 4 weeks&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
          -  No uncontrolled angina&#xD;
&#xD;
          -  No myocardial infarction and/or stroke within the past 6 months&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No evidence of clinically active interstitial lung disease&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No history of gastrointestinal bleeding within the past 6 months&#xD;
&#xD;
          -  No history of peptic ulcer disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Must weigh at least 110 pounds (50 kg)&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No allergy to sulfonamides&#xD;
&#xD;
          -  No allergy to any NSAID, including celecoxib&#xD;
&#xD;
          -  No known severe hypersensitivity to gefitinib or any of its excipients&#xD;
&#xD;
          -  No other malignancy within the past 3 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No history of dementia, active psychiatric disorder, or any other condition that would&#xD;
             preclude study compliance&#xD;
&#xD;
          -  No other concurrent serious medical condition&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior epidermal growth factor receptor inhibitor&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 2 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  More than 2 weeks since prior investigational therapy&#xD;
&#xD;
          -  More than 1 week since prior fluconazole&#xD;
&#xD;
          -  More than 30 days since prior participation in another investigational agent clinical&#xD;
             trial&#xD;
&#xD;
          -  More than 30 days since prior chronic nonsteroidal anti-inflammatory drugs (NSAIDs),&#xD;
             including celecoxib or rofecoxib&#xD;
&#xD;
          -  No prior gefitinib&#xD;
&#xD;
          -  No prior cyclooxygenase-2 (COX-2) inhibitor or another clinical trial for NSCLC&#xD;
&#xD;
          -  No other concurrent NSAIDs&#xD;
&#xD;
               -  Concurrent aspirin allowed (not to exceed 325 mg/day)&#xD;
&#xD;
          -  No other concurrent COX-2 inhibitors&#xD;
&#xD;
          -  No concurrent lithium&#xD;
&#xD;
          -  No concurrent fluconazole&#xD;
&#xD;
          -  No concurrent use of any of the following:&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Barbiturates&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Hypericum perforatum&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shirish M. Gadgeel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>September 10, 2003</study_first_submitted>
  <study_first_submitted_qc>September 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2003</study_first_posted>
  <last_update_submitted>April 25, 2013</last_update_submitted>
  <last_update_submitted_qc>April 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

